TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
systematic review
meta-analysis
network meta-analysis
Select
abdominal aortic aneurysm
acute coronary syndrome
acute heart failure
acute myocardial infarction
advanced breast cancer (metastatic)
atrial fibrillation
atrioventricular block or sick sinus syndrome
CABG surgery
cardiac arrest
cardiovascular prevention
coronary artery disease
diabetes type 2
diabetic kidney disease
Head and neck cancer
heart failure
hypertension
miscellaneous
multiple myeloma
obesity and overweight
patients at high risk for cardiovascular events
percutaneous coronary intervention
peripheral vascular diseases
post acute coronary syndromes
post myocardial infarction
prevention of sudden death
pulmonary embolism
restenosis after PCI
stable angina
stent
superficial thrombophlebitis
thrombosis prevention
throracic aortic aneuvrism
venous thrombosis
a
acarbose
acetamin
acute short term calcium blockers
angiotensin receptor blocker
angiotensin-converting enzyme inhibitors
anti-agrégant
antiarryhtmic
antibiotics
anticoagulant
anticoagulants + antiplatelet agents
antioxydant
antiplatelet drugs
antivitamins K
ARBs added to ACEI
beta radiation
beta-blockers + diuretics
beta-blockers or diuretics
BNP-guided management
CABG
calcium-channel blockers
cardiac resynchronization therapy
Catheter aspiration devices
CETP inhibitor
Combined CRT + ICD
compression-only CPR
cooling-off strategy
diet
diuretics
docetaxel based induction CT
double stenting
drug-eluting stents
early angioplasty (<3 days) after thrombolysis
early invasive strategy
embolic protection devices
endothelin receptor antagonist
endovascular repair
Enzyme therapy
Essaven
Etofenak
exercise training
Exhirud
extended prophylaxis
fibrinolysis
fibrinolytic
Fixed-dose LMWH
Fluoxetine
gamma radiation
GCS (adjunctive therapy)
GIK infusion
GP IIaIIIb inhibitors
Graduated compression stockings
Heparansulphate
heparin
home treatment
hydralazine-ISDN
Implantable cardioverter defibrillator therapy
induced HbA1c reduction
induction polyCT with platin
induction polyCT without platin
intensive treatment
Interleukin-1ß inhibition
intravenous nitrates
IPC adjunctive therapy
IPC monotherapy
Larynx preservation
LLA closure
Long term treatment
Low molecular weight heparin
Mechanical thrombectomy devices
Multiple risk factor interventions
non-polymeric ES
NSAIDs
omega-3 Fatty acids
oral anticoagulant
oral platelet GP IIbIIIa receptor inhibitor
other cholesterol lowering drugs
other induction CT
Others class I
pacemaker
PCI
PF induction CT
Phosphodiesterase III inhibitors
plasma homocysteine lowering intervention
platelet aggregation inhibitors
prazosin
Prehospital thrombolysis
pretreatment with statin
primary PCI
prolonged dual antiplatelet therapy
prophylactic lidocaine
Prophylactic LMWH
repeat fibrinolysis
rescue PCI
resordable
Rhythm control
rimonabant
screening for CAD
short term LMWH
spinal cord stimulation
statins
stem cells
surgery
sympathectomie avec chirurgie
synthetic oligosaccharide
systemic fibrinolysis
telemonitoring
tesofensine
Therapeutic LMWH
thrombectomy
Topical methylthioadenosine
transfer for primary angioplasty
transmyocardial revascularization
triple antiplatelet
Vasotonin
vs angioplasty
vs antithrombotics
vs control
vs control or placebo
vs conventional PCI
vs LMWH
vs no anticoagulant
vs no screening
vs no systematic PCI
vs on pump CABG
vs pentascharide
vs placebo
vs placebo or control
vs placebo or no treatment
vs standard strategy
vs surveillance
vs usual care
vs active treatment
vs angiotensin-converting enzyme inhibitors
vs anticoagulant
vs antiplatelet drugs
vs calcium blockers
vs calcium-channel blockers
vs dextran
vs diuretic and/or beta-blocker
vs diuretic or beta-blocker
vs diuretics
vs drug-eluting stents
vs fondaparinux
vs GCS
vs ICD
vs IPC
vs Low molecular weight heparin
vs no TMR
vs non active control
vs open surgery
vs other fibrinolytic
vs rate control
vs short antiplatelet drug
vs single stenting
vs standard CPR
vs surgery
vs thrombolytic
vs UFH
vs Unfractionated heparin
early initiation
secondary prevention
pdf
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
All cause death (854)
stroke (fatal and non fatal) (305)
death (overall survival) (283)
myocardial infarction (fatal and non fatal) (244)
cardiovascular events (226)
treatment related death (209)
Major bleeding (207)
sustained response at 24hr (197)
response at 2h (197)
response at 4h (197)
headache recurrence (197)
any adverse event (197)
pain free at 2h (197)
pain free at 4h (197)
nausea (197)
fatigue (197)
chest symptoms (197)
use of rescue medication (197)
response at 4h without additionnal treatment (197)
pain free at 1h (197)
use of a second dose (197)
response at 1h (197)
somnolence (197)
Neck tightness (197)
dizziness (197)
sustained pain-free at 24h (197)
NPI at 6 months (193)
Amputation (179)
Cardiovascular death (172)
Bleeding (172)
death or laryngectomy (164)
withdrawals due to an adverse event at 24 weeks (161)
ADAS-COG at 6 months (152)
Adverse events (148)
progression or death (progression free survival PFS) (141)
ADAS-COG at 12 weeks (138)
Global improvement (129)
Treatment related complication (128)
NPI at 3 months (123)
DAD at 6 months (123)
Wound infection (116)
cancer related death (112)
laryngectomy (108)
disease free survival (108)
death of unknown cause (108)
Patient Global Impression of Improvement (PGI-I) (108)
CGI-severity (108)
Sheehan disability scale (108)
Douleur (108)
FIQ (108)
Fatigue (108)
Points douloureux (nombre) (108)
amélioration globale (patient) (108)
amélioration globale (clinicien) (108)
Sommeil (108)
Dépression (108)
Anxiété (108)
Severité globale (108)
HAQ functional disability (108)
complete response to study treatment (107)
larynx preservation (107)
complete response to induction CT (107)
Non fatal MI (105)
Allergic reactions (103)
death or event (event free survival) (101)
thrombotic events (101)
relapse (101)
Severe allergic reactions (101)
Pancreatitis (101)
Diabetes (101)
Hyperglycemia (101)
remission failure after induction (101)
second malignancy (101)
severe infection (101)
Long term death (99)
hospitalisation for heart failure (97)
Urinary infection (90)
Sudden death (88)
cardiac death (87)
Non fatal stroke (85)
Coronary event (79)
Deep vein thrombosis (79)
Revascularization (78)
Coronary death (75)
relief of abdominal pain (71)
MACE (69)
Postoperative intra abdominal abcess (62)
CABG (59)
reinfarction (59)
Survival with functional larynx (59)
Infection (58)
Heart failure (58)
Deaths or MI (56)
Intraperitoneal abces (54)
pneumonia (54)
infection related death (54)
perineal infection (54)
fistula (54)
peritonitis (54)
Fatal MI (52)
long term MI (52)
Stent thrombosis (any, end of follow up) (49)
neutropenia (grade 3-4) during induction CT (48)
Sepsis (47)
SBP change from baseline (mmHG) (43)
DBP change from baseline (mmHg) (43)
Venous thromboembolism (41)
Minor bleeding (40)
non cardiovascular death (40)
pulmonary embolism (symptomatic and asymptomatic) (40)
Adverse events leading to treatment discontinuation (39)
Smoking prevalence (38)
blood cholesterol concentration (38)
Fatal stroke (37)
Cancer (37)
Bacteriuria (35)
Febrile morbidity (35)
Bacteremia (35)
In-hospital death (34)
2 yr MACE (34)
atrial fibrillation (34)
Abdominal infection (33)
microvascular events (33)
heart failure death (33)
PTCA (32)
A CHANGER (31)
Pacemaker syndrome (31)
Death from any cause or hospitalization for any reason (30)
diarrhoea (30)
target lesion revascularisation (30)
Death from any cause or hospitalization for heart failure (29)
angiographic restenosis (29)
target-vessel revascularization (29)
death or nonfatal CHF events (29)
vomiting (28)
death or hospitalization for cardiac causes (28)
intracranial hemorrhage (27)
Pro-arrhythmia (27)
Atrial fibrillation recurrence (27)
Cardiac nonarrhythmic death (27)
Cardiac arrhythmic death (27)
Vascular noncardiac death (27)
hospitalization for AF (27)
vitesse de croissance SDS (27)
urgent CABG (26)
In-hospital MI (26)
1 year death from any cause (25)
long term cardiovascular events (25)
Hospitalization for any reason (25)
macrovascular events (25)
MMSE at 6 months (25)
death or disease progression (progression free survival) (25)
All grade3-4 events during study treatment (25)
cardiac event (fatal and non fatal ) (24)
macrovascular or microvascular events (24)
Toxic death during induction CT (23)
treatment failure (23)
All grade 3 to 4 events during induction CT (23)
Venous thromboembolism end of treatment (23)
Extension and/or recurrence of SVT (23)
Heparin-induced thrombocytopenia (23)
Pain disappearance (23)
In-hospital death (22)
Vascular death (21)
ischemic stroke (21)
NYHA class improvement (21)
4 yr mortality from all causes (21)
4 yr MI (21)
4 yr TLR (21)
4 yr death or MI (21)
4 yr stent thrombosis (21)
4y stent thrombosis (ARC) (21)
2 yr TLR (21)
2 yr Death (all cause) (21)
late stent thrombosis (31days - 1year) (21)
Acute stent thrombosis (<=24h) (21)
sub acute stent thrombosis (1-30 days) (21)
in-lesion binary restenosis (21)
Fatal bleeding (20)
Extracranial hemorrhage (20)
taille en fin d'essai (cm) (20)
vitesse de croissance (1 an) (20)
taille en fin d'essai SDS (20)
taille définitive SDS (20)
changement taille (cm) (20)
taille définitive (cm) (20)
recurrent angina (19)
Symptomatic pulmonary embolism (19)
Haemmorhagic stroke (18)
fatal pulmonary embolism (18)
Vascular events (17)
(17)
Relief of constipation (17)
asymptomatic DVT (17)
Symptomatic venous thromboembolism (DVT, PE) (17)
hospitalisation for cardiovascular causes (17)
major or clinically relevant non-major bleeding (16)
CIBIC-Plus or CGIC (numbers improved) at 24 weeks (16)
exacerbation of heart failure (16)
Angina relief (16)
Angina class improvement + death (16)
Stroke or MI (15)
Fasting glucose change (mmol/liter) (15)
weight loss equal to or greater than 5 percent (15)
weight loss equal to or greater than 10 percent (15)
weight change from baseline (kg) (15)
non-fatal pulmonary embolism (15)
Death or stroke or myocardial infarction (15)
SIB score at 6 months (15)
CDR-SB at 24 weeks (15)
CDR-SB at 12 weeks (15)
maximal walking distance (14)
pain-free walking distance (14)
Non vascular death (14)
wound haematoma / infection (14)
ADCS-ADL-severe at 6 months (14)
agitation (14)
death from cardiovascular causes or hospitalization for cardiovascular causes (14)
fatal ventricular fibrillation (14)
fatal and non fatal ventricular fibrillation (14)
non fatal VF (14)
GI adverse events (13)
Occlusion (13)
Precoce death or MI (13)
In hospital death or MI (13)
Recurrent thromboembolic event (13)
total VTE and all-cause mortality (13)
6 months events (13)
1 year event (13)
6 months death (13)
6 months MI (13)
1 year MI (13)
1 year revascularization (13)
changement taille SDS (13)
succès thérapeutique (13)
changement vitesse de croissance (cm/an) (13)
changement vitesse de croissance SDS (13)
hyperhemia or ocular redness (13)
IOP at end (mmHg) (13)
IOP change at 3 mo, absolute (mmHg) (13)
IOP at 3 months (mmHg) (13)
1-year death or MI (12)
In hospital non fatal MI (12)
Positive 6-wk ETT (12)
no angina (at 6 weeks) (12)
CCS class III-IV angina (12)
rehospitalization (12)
Death, MI, stroke, refractory ischemia (12)
Repeat intervention (12)
long term cardiovascular death (12)
long term all cause death, MI (12)
no change or worsening in CIBIC+ at 6 month (12)
MMSE at 12 weeks (12)
NYHA change (12)
LV ejection fraction (12)
serious hyperkalemia (12)
exercise capacity (12)
death from cardiovascular causes or hospitalization for heart failure (12)
death associated with abdominal aortic aneurysms (11)
less than 4 points improvement in ADAS-cog at 6 months (11)
all cause death, MI, thrombo-embolic stroke (11)
proximal DVT (11)
stroke or TIA (10)
Diabetes onset (10)
Hypotension (10)
transfusion (10)
weight change from baseline (%) (10)
HbA1c (10)
Symptomatic deep-vein thrombosis (10)
augmentation de la distance de claudication initiale (9)
augmentation de la distance de claudication (9)
Cardiovascular death or hospital admission for CHF (9)
Worsening heart failure (9)
Transplantation (9)
Arrhythmia (9)
Vertigo (9)
death or severe congestive heart failure (8)
30-day death (8)
GBS at 52 weeks (8)
MMSE at 52 weeks (8)
long term institutionalisation at 52 weeks (8)
adverse event at 1 year (8)
VTE (8)
puylmonary embolism (8)
Late lumen loss (8)
Change in MLD (8)
5-year death (8)
7-year death (8)
10-year death (8)
Surgical revascularization (7)
End stage renal disease (7)
non pulmonary embolism death (7)
Short term haemorrhage (7)
Thrombus extension (7)
new-onset diabetes (7)
Peripheral embolism (7)
Atrial fibrillation follow-up (7)
combined endpoint (7)
death by cardiac arrhythmia (7)
thrombo-embolic event (cerebral or systemic) (6)
TE event or ischemic stroke or systemic embolism (6)
Angina (6)
Perioperative stroke or death (6)
Perioperative stroke or death or subsequent ipsilateral stroke (6)
Perioperative stroke or death or any subsequent stroke (6)
stroke or death (6)
CIBIC+ score at 6 months (6)
death, reinfarctus, stroke (6)
Death, MI, ischameia (6)
Emergency CABG (6)
Reocclusion (6)
Algo-functional Index (AFI) (6)
NSAID consumption (6)
Pain at rest (VAS) (6)
Pain during activity (VAS) (6)
OMERACT-OARSI responders (6)
WOMAC index (6)
Pain during activity at 3 months (6)
Pain during activity at 6 months (6)
EVA (6)
AFI (6)
Non cerebral major bleeding (5)
Peripheral arterial disease (5)
évenement stoxiques cardiaques (5)
Waist circumference change from baseline (cm) (5)
Cough (5)
Hyperkalaemia (5)
(5)
angiodema (5)
death or cardiovascular hospitalization (5)
Death from cancer (5)
Ventricular fibrillation (5)
II-III atrio ventricular block (5)
Cardiogenic shock (5)
severe arrhythmia (5)
Bradycardia (5)
Flushing (5)
Total exercise duration (s) (5)
Time to angina onset (s) (5)
Time to 1 mm ST depression (s) (5)
Angina episodes per week (5)
Nitroglycerin use per week (5)
Acute coronary syndrome (4)
long term aneurysm-related death (4)
In hospital aneurysm-related death (4)
lung cancer (4)
breast cancer (4)
prostate cancer (4)
myocardial infarction or death (4)
death, myocardial infarction, or recurrent at 14 days (4)
death, myocardial infarction, or recurrent at 30 days (4)
death at 30 days (4)
myocardial infarction at 30 days (4)
Drop in platelet count of 50% (4)
All-cause hospitalisation (4)
Serious adverse event (4)
Amelioration of Dyspnea at 6 h (4)
amelioration of Dyspnea at 24 h (4)
Coronary death and non fatal MI (4)
LDL (4)
HDL (at 1 y) (4)
total cholesterol (at 1 y) (4)
Myopathy (4)
Rhabdomyolysis (4)
distal DVT (4)
death or hospitalization (4)
BNP under treatment (4)
CV death, MI hospitalization for HF (4)
systemic thrombo-embolic complication (3)
hypertransaminasemia (3)
Lifethreatening major bleeding (3)
Non-lifethreatening major bleeding (3)
Gastrointestinal major bleeding (3)
cardiovascular events at 1 month (3)
cardiovascular events at 4 months (3)
Death or any stroke within 30 days (3)
Death or disabling stroke within 30 days (3)
Death within 30 days (3)
Stroke within 30 days (3)
Cranial neuropathy within 30 days (3)
Death or neurological complication within 30 days (3)
Death or any stroke (during follow up) (3)
Death during follow up (3)
Stroke during follow up (3)
long term restenosis (3)
long term stroke (3)
long term fatal stroke (3)
non-perioperative ipsilateral stroke (3)
proximal deep-vein thrombosis (3)
Venous thromboembolism or death (3)
net benefit (3)
early death (3)
Initial TIMI 3 flow (3)
Final TIMI 3 flow (3)
urgent target vessel revascularisation (3)
Cardiac death or MI (3)
any bleedings (3)
Survival to hospital discharge (3)
favorable neurologic outcome at discharge (3)
Return of spontaneous circulation (3)
long-term survival (3)
change in maximum CIMT (3)
change in mean CIMT (3)
Coronary revascularization (3)
Carotid revascularization (3)
cardiovascular events including revascularization (3)
Amputations (2)
rest HR (2)
RP product at rest (2)
carotide IMT (2)
Growth rate in mm/year (2)
all cause death, MI, stroke (2)
short term death (2)
non cardiac death (2)
unstable angina (2)
new cardiac revascularization (2)
Rey auditory verbal learnin (2)
Grooved Pegboard (2)
Trail A test (2)
Trail B test (2)
Digit Symbol test (2)
graft occlusion (2)
stent thrombosis (2)
Cardiovascular death/MI/stent thrombosis (2)
GUSTO severe/moderate bleeding (2)
vertebral fractures (2)
clinical vertebral fractures (2)
hip fractures (2)
major non vertebral fractures (2)
non vertebral fractures (2)
1-year vertebral fracture (2)
1-year non vertebral fracture (2)
morphometric vertebral fractures (2)
major non vertebral fractures (imputed) (2)
death from all causes as adverse event (2)
serious adverse events (2)
cardiovascular events as adverse event (2)
neurological SAE (2)
Neurocognitive disorder (2)
Muscle-related adverse events (2)
cardiovascular death as adverse event (2)
myocardial infarction as adverse event (2)
unstable angina as adverse death (2)
long term revascularization (1)
retinopathy (1)
vision loss (1)
Mortality (early) (1)
Pulmonary embolism (early) (1)
Bleeding (early) (1)
Any improvement in venous patency (early) (1)
Complete clot lysis (early) (1)
Stroke/intracerebral bleeding (early) (1)
Leg ulceration (late) (1)
Mortality (late) (1)
Post-thrombotic syndrome (late) (1)
Complete clot lysis (late) (1)
Normal venous function (late) (1)
confirmed myocardial infarction (1)
MI (CK-MB >3x ULN at 6 and 12 hours after PCI) (1)
MI (troponin I >3x ULN at 6 and 12 hours after PCI) (1)
Myocardial ischemia (1)
refractory ischemia (1)
fatal bleeding (1)
death, MI, unplanned revascularization (1)
ischemic events + bleeding (1)
major bleeding TIMI (1)
TIMI minor bleeding (1)
Urgent target-vessel revascularization (1)
Major or minor TIMI bleeding (1)
Death, MI and stroke (1)
cardiovascular death, MI, stroke (1)
new-onset atrial fibrillation (1)
death or vein graft failure (1)
device retrieval, pericardial effusion, major bleeding (1)
stroke, cardiovascular or unexplained death, systemic embolization (1)
symptomatic venous thromboembolism at the end of treatment (1)
recurrent symptomatic venous thromboembolism and death at the end of treatment (1)
Recurrent Symptomatic Venous Thromboembolism or death (1)
major VTE (fatal and non fatal DVT,PE) (1)
progression (Time to progression TTP) (1)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
All cause death
stroke (fatal and non fatal)
×
Modal title